S&P 500

5.222,68

0,16%

Negocie como um profissional: Aproveite discussões em tempo real e ideias que movimentam o mercado para superar a concorrência.

Cadastre-se

Início
Investir
Ações
EUA
NYSE
Annovis Bio Inc (ANVS)
Annovis Bio Inc (ANVS) Notícias

ANVS

Annovis Bio (ANVS)

Annovis Bio Inc

De:

Notícias regulamentadas

Procure um Texto:

Ordenação:

Notícias não regulamentadas

Apresentando as notícias mais relevantes sobre:NYSE:ANVS

1 2 3 4 Próxima >>

Data	Hora	Fonte	Título	Código	Companhia
10/05/2024	18:11	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NYSE:ANVS	Annovis Bio Inc
09/05/2024	17:03	Edgar (US Regulatory)	Form 8-K - Current report	NYSE:ANVS	Annovis Bio Inc
09/05/2024	08:30	GlobeNewswire Inc.	Annovis Announces Unblinding of the Buntanetap Phase III Data in Parkinson’s Disease	NYSE:ANVS	Annovis Bio Inc
06/05/2024	18:12	Edgar (US Regulatory)	Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material	NYSE:ANVS	Annovis Bio Inc
06/05/2024	08:30	GlobeNewswire Inc.	Annovis Bio CEO Maria Maccecchini Issues Letter to Stockholders	NYSE:ANVS	Annovis Bio Inc
29/04/2024	11:10	GlobeNewswire Inc.	Annovis Bio Announces Statistically Significant Phase II/III Data in Patients With Early Alzheimer’s Disease	NYSE:ANVS	Annovis Bio Inc
02/04/2024	08:30	GlobeNewswire Inc.	Annovis Bio Provides Corporate Updates and Reports Fourth Quarter and Full Year 2023 Financial Results	NYSE:ANVS	Annovis Bio Inc
28/02/2024	09:08	IH Market News	US Stock Movers Before Market: Beyond Meat, eBay, First Solar, Urban Outfitters…	NYSE:ANVS	Annovis Bio Inc
12/02/2024	16:00	Edgar (US Regulatory)	Form S-3/A - Registration statement under Securities Act of 1933: [Amend]	NYSE:ANVS	Annovis Bio Inc
01/02/2024	18:05	Edgar (US Regulatory)	Form S-3 - Registration statement under Securities Act of 1933	NYSE:ANVS	Annovis Bio Inc
22/11/2023	18:27	Edgar (US Regulatory)	Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]	NYSE:ANVS	Annovis Bio Inc
21/11/2023	16:33	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NYSE:ANVS	Annovis Bio Inc
02/11/2023	08:30	Business Wire	Annovis Bio Measures Novel Biomarkers in Plasma of Parkinson’s Patients	NYSE:ANVS	Annovis Bio Inc
01/11/2023	13:24	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NYSE:ANVS	Annovis Bio Inc
31/10/2023	09:00	Business Wire	Annovis Bio Announces Pricing of $7.5 Million Public Offering	NYSE:ANVS	Annovis Bio Inc
30/10/2023	17:48	Business Wire	Annovis Bio Announces Launch of Proposed Public Offering	NYSE:ANVS	Annovis Bio Inc
30/10/2023	17:42	Business Wire	Annovis Bio Receives Positive Recommendation to Continue Phase 2/3 Trial of Buntanetap for Alzheimer’s Disease Patients From the Independent Data and Safety Monitoring Board (DSMB)	NYSE:ANVS	Annovis Bio Inc
24/10/2023	10:13	Business Wire	Annovis Bio Showcases Promising Progress in Novel Drug Development at the 2023 Clinical Trials on Alzheimer's Disease Conference	NYSE:ANVS	Annovis Bio Inc
21/09/2023	10:35	GlobeNewswire Inc.	Dawson James Securities Announces October Date for 8th Annual Small Cap Growth Conference	NYSE:ANVS	Annovis Bio Inc
15/08/2023	08:20	Business Wire	Annovis Bio Announces Second Quarter 2023 Financial Results and Provides Corporate Update	NYSE:ANVS	Annovis Bio Inc
18/07/2023	09:18	Business Wire	Continued Positive Performance of Novel Drug Development by Annovis Bio Presented at 2023 Alzheimer's Association International Conference	NYSE:ANVS	Annovis Bio Inc
27/06/2023	08:30	Business Wire	Annovis Bio Announces the Filing of a Groundbreaking Patent	NYSE:ANVS	Annovis Bio Inc
20/06/2023	13:05	Business Wire	Annovis Bio Receives Excellent Safety Rating and Positive Recommendation to Continue Phase III Trial of Buntanetap for Parkinson’s Disease Patients from the Independent Data and Safety Monitoring Board (DSMB)	NYSE:ANVS	Annovis Bio Inc
16/06/2023	17:19	Edgar (US Regulatory)	Current Report Filing (8-k)	NYSE:ANVS	Annovis Bio Inc
08/06/2023	08:30	PR Newswire (US)	Annovis Bio Announces Completion of Phase III Parkinson's Disease Treatment Enrollment at Record Pace	NYSE:ANVS	Annovis Bio Inc
10/05/2023	17:35	Edgar (US Regulatory)	Quarterly Report (10-q)	NYSE:ANVS	Annovis Bio Inc
28/04/2023	09:01	Edgar (US Regulatory)	Proxy Statement (definitive) (def 14a)	NYSE:ANVS	Annovis Bio Inc
26/04/2023	17:34	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NYSE:ANVS	Annovis Bio Inc
25/04/2023	07:01	Edgar (US Regulatory)	Small Company Offering and Sale of Securities Without Registration (d)	NYSE:ANVS	Annovis Bio Inc
06/01/2023	09:30	PR Newswire (US)	Annovis Bio Announces New Appointments to Strengthen Its Senior Leadership Team	NYSE:ANVS	Annovis Bio Inc